AstraZeneca vs AXA: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and AXA side by side

1. 1817AXA

   Founding of the Compagnie d'Assurances Mutuelles contre l'Incendie

   Jacques-Théodore le Carpentier and 17 other property owners in Rouen set up a mutual fire insurance company, the earliest predecessor of AXA. It stayed a Normandy mutual, later called Ancienne Mutuelle, for more than a century.

2. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

3. 1975AXA

   Claude Bébéar becomes chief executive

   Bébéar, recruited in 1958 by André Sahut d'Izarn, took over the Anciennes Mutuelles group in 1975 after Sahut d'Izarn's death and the settlement of a strike that had paralysed the company in April 1974.

4. 1982AXA

   Takeover of the Drouot Group

   Bébéar took control of the Drouot Group, then the leading private French insurance group, and became its chairman alongside his role at Mutuelles Unies.

5. 1985AXA

   Creation of the AXA name

   The group adopted the invented name AXA, short and pronounceable in any language, and Bébéar moved from running the insurance companies to chairing the group.

6. 1986AXA

   Acquisition of the Présence Group

   AXA bought the Présence Group in April 1986, continuing the consolidation of French insurers.

7. 1988AXA

   Merger with Compagnie du Midi

   The merger with Compagnie du Midi made AXA the second-largest French insurance group behind UAP and brought Equity and Law, then the sixth-largest life insurer in the United Kingdom. Bébéar was elected Manager of the Year the same year.

8. 1991AXA

   Control of The Equitable in the United States

   After a failed attempt to buy Farmers, AXA agreed in July 1991 to demutualise and take control of The Equitable, then the fifth-largest life insurer in the United States, which also brought Alliance Capital Management.

9. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

10. 1996AXA

    Acquisition of UAP

    AXA bought UAP, a French insurer twice its size, doubling its French business and reaching critical mass in the United Kingdom, Belgium and Germany. The merger took effect in 1997.

11. 1999AstraZeneca

    Astra and Zeneca Merge to Form AstraZeneca

    The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

12. 1999AXA

    Guardian Royal Exchange and Nippon Dantai

    Guardian Royal Exchange joined AXA in early 1999, adding scale in United Kingdom property, casualty and health insurance, and AXA took control of Nippon Dantai, then the thirteenth-largest life insurer in Japan.

13. 2000AstraZeneca

    Nexium Launch Replaces Prilosec

    AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

14. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

15. 2006AXA

    Acquisition of Winterthur

    AXA agreed to buy Winterthur from Credit Suisse for ~$14.8 billion (CHF 12.3 billion), about $8.93 billion (EUR 7.9 billion) in cash, strengthening its position in Switzerland, Germany and central and eastern Europe.

16. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

17. 2011AXA

    Sale of AXA Canada

    AXA sold its Canadian operations to Intact Financial Corp. for ~$1.87 billion (C$2.6 billion) as part of a portfolio review.

18. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

19. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

20. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

21. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

22. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

23. 2018AXA

    Acquisition of XL Group

    AXA bought XL Group for $15.3 billion in cash, shifting the group toward commercial property and casualty lines and creating the AXA XL platform.

24. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

25. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

26. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

27. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

28. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

29. 2024AXA

    Launch of the Unlock the Future plan

    With its 2023 results in February 2024 AXA presented a 2024 to 2026 plan targeting underlying earnings per share growth of 6% to 8% a year, an underlying return on equity of 14% to 16% and a new capital management policy.

30. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

31. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

32. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

33. 2025AXA

    Sale of AXA Investment Managers to BNP Paribas

    AXA completed the sale of AXA Investment Managers to BNP Paribas Cardif on July 1, 2025 for ~$5.76 billion (EUR 5.1 billion) in cash, a total transaction value of ~$6.1 billion (EUR 5.4 billion), and signed a long-term agreement for BNP Paribas to manage a lar…

34. 2025AXA

    Death of founder Claude Bébéar

    AXA announced on November 4, 2025 that Claude Bébéar, its founder and Honorary Chairman, had died at the age of 90. He ran the group from 1975 to 2000 and created the AXA name in 1985.

35. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

36. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

37. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about AstraZeneca vs AXA